146 related articles for article (PubMed ID: 489709)
1. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone.
Barone RM; Shamonki IM; Siiteri PK; Judd HL
J Clin Endocrinol Metab; 1979 Nov; 49(5):672-6. PubMed ID: 489709
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of delta 1-testololactone on peripheral aromatization.
Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL
Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208
[TBL] [Abstract][Full Text] [Related]
3. Origin of serum estradiol in postmenopausal women.
Judd HL; Shamonki IM; Frumar AM; Lagasse LD
Obstet Gynecol; 1982 Jun; 59(6):680-6. PubMed ID: 7078905
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of estrogen synthesis in human breast tumors by testololactone and bromoandrostenedione.
Budnick RM; Dao TL
Steroids; 1980 May; 35(5):533-41. PubMed ID: 7394858
[TBL] [Abstract][Full Text] [Related]
5. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
Dao TL
Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
[TBL] [Abstract][Full Text] [Related]
6. Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer.
Judd HL; Lucas WE; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):272-8. PubMed ID: 950362
[TBL] [Abstract][Full Text] [Related]
7. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of peripheral aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962).
Longcope C; Femino A; Johnston JO
Endocrinology; 1988 May; 122(5):2007-11. PubMed ID: 3359974
[TBL] [Abstract][Full Text] [Related]
10. Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women.
Lønning PE; Dowsett M; Jacobs S; Schem B; Hardy J; Powles TJ
J Steroid Biochem; 1989; 34(1-6):551-3. PubMed ID: 2626050
[TBL] [Abstract][Full Text] [Related]
11. Androgen-estrogen production rates in postmenopausal women with breast cancer.
Kirschner MA; Cohen FB; Ryan C
Cancer Res; 1978 Nov; 38(11 Pt 2):4029-35. PubMed ID: 568029
[No Abstract] [Full Text] [Related]
12. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
[TBL] [Abstract][Full Text] [Related]
13. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer.
Nagamani M; Hannigan EV; Dillard EA; Van Dinh T
J Clin Endocrinol Metab; 1986 Mar; 62(3):508-12. PubMed ID: 3944235
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of peripheral aromatization in postmenopausal women with breast cancer.
Barone RM; Judd HL
Surg Forum; 1978; 29():172-4. PubMed ID: 401126
[No Abstract] [Full Text] [Related]
15. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
16. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
[TBL] [Abstract][Full Text] [Related]
17. Enhanced conversion of androstenedione to estrogens in obese males.
Kley HK; Deselaers T; Peerenboom H; Krüskemper HL
J Clin Endocrinol Metab; 1980 Nov; 51(5):1128-32. PubMed ID: 7419688
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls.
Adami HO; Johansson ED; Vegelius J; Victor A
Ups J Med Sci; 1979; 84(3):259-74. PubMed ID: 575585
[TBL] [Abstract][Full Text] [Related]
19. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women.
Leder BZ; Leblanc KM; Longcope C; Lee H; Catlin DH; Finkelstein JS
J Clin Endocrinol Metab; 2002 Dec; 87(12):5449-54. PubMed ID: 12466335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
